Literature DB >> 31135826

Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration.

Sarah S P DiMagno1, Aaron Glickman1, Ezekiel J Emanuel1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31135826     DOI： 10.1001/jamainternmed.2019.0584

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

1.  Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab.

Authors:  Emily A Largent; Andrew Peterson; Jason Karlawish; Holly Fernandez Lynch
Journal:  Drugs Aging       Date:  2022-06-13       Impact factor: 4.271

Review 2.  Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

Authors:  Elihu Estey; Judith E Karp; Ashkan Emadi; Megan Othus; Robert Peter Gale
Journal:  Leukemia       Date:  2020-01-08       Impact factor: 12.883

3.  Manufacturers' views on outcome-based agreements.

Authors:  Sahar Barjestehvan Waalwijk van Doorn-Khosrovani; Lonneke Timmers; Anke Pisters-van Roy; Joël Gijzen; Nicole M A Blijlevens; Haiko Bloemendal
Journal:  J Mark Access Health Policy       Date:  2021-10-29

4.  Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness.

Authors:  Melanie McPhail; Emma Weiss; Tania Bubela
Journal:  Front Med (Lausanne)       Date:  2022-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.